Results 111 to 120 of about 50,426 (246)

Serum Interleukin-4 and Total Immunoglobulin E in Nonatopic Alopecia Areata Patients and HLA-DRB1 Typing [PDF]

open access: yes, 2010
Background. Interleukin-4 (IL-4), a Th2 cytokine, can stimulate immunoglobulin E (IgE) transcription. No previous studies evaluated the genetic mechanisms in nonatopic AA patients with elevated serum IgE. Objective.
Attia, Enas A. S.   +2 more
core   +3 more sources

A Novel Hope for Alopecia Totalis Patients: Case Report [PDF]

open access: diamond, 2020
Manal Elsayed   +3 more
openalex   +1 more source

Genotype–Phenotype Correlations, Mortality, and Clinical Insights in Keratitis–Ichthyosis–Deafness Syndrome: A Comprehensive Review and Case Report

open access: yesAmerican Journal of Medical Genetics Part A, Volume 197, Issue 11, November 2025.
ABSTRACT Keratosis–ichthyosis–deafness (KID) syndrome is a rare autosomal dominant ectodermal disease caused by mutations in the GJB2 gene, which encodes the gap junction protein Connexin 26 (Cx26) located on Chr. 13q12.11. This study presents the first mortality analysis associated with KID syndrome, focusing on a case report of a Latin American ...
Leslie Patrón‐Romero   +17 more
wiley   +1 more source

Alopecia: evaluation and treatment [PDF]

open access: yes, 2011
Hair loss is a very common complaint. Patients may describe increased shedding and diffuse or localized alopecia. The differential diagnosis of hair loss includes a number of disorders causing cicatricial or noncicatricial alopecias. This paper describes
Gordon, Katherine A, Tosti, Antonella
core   +2 more sources

Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise

open access: yesAustralasian Journal of Dermatology, Volume 66, Issue 7, Page 404-412, November 2025.
ABSTRACT Background/Objectives Janus kinase inhibitors (JAKis) have been approved by the Therapeutic Goods Administration for severe alopecia areata (AA) in Australia. However, access is limited as JAKis are not currently subsidised on the Pharmaceutical Benefits Scheme for this indication. This study aimed to establish expert consensus on criteria for
Meryl Thomas   +23 more
wiley   +1 more source

Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older

open access: yesActas Dermo-Sifiliográficas
Alopecia areata (AA) is a dermatological disease of immune origin characterized by partial or total hair loss of the scalp (alopecia totalis) or the whole body (alopecia universalis).
S. Vañó-Galván   +5 more
doaj   +1 more source

Alopecia Areata and Systemic Lupus Erythematosus: Insights From a Nationwide Case–Control Study

open access: yes
International Journal of Dermatology, Volume 65, Issue 1, Page 152-153, January 2026.
Yonit Wohl   +4 more
wiley   +1 more source

Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement

open access: yesAustralasian Journal of Dermatology, Volume 66, Issue 7, Page e444-e460, November 2025.
ABSTRACT Over 5000 patients are newly diagnosed with Alopecia areata (AA) in Australia each year. AA severity varies from a single small patch to complete loss of scalp hair, body hair including eyelashes and eyebrows. Approximately 40% of affected individuals experience only a single patch and achieve spontaneous, complete and durable remission within
Daniella Kushnir‐Grinbaum   +19 more
wiley   +1 more source

Colloquy [PDF]

open access: yes, 1987
Webster\u27s Dictionary defines colloquy as mutual discourse . Readers are encouraged to submit additions, corrections, and comments about earlier articles appearing in Word Ways.

core   +1 more source

SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata

open access: yes
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 1, Page e5-e7, January 2026.
Ziad Reguiai   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy